Health & Biotech
Respiri Limited (ASX: RSH) are an Australian owned company with smart tools to empower people with asthma and improve outcomes.
Backed by over twenty years of research by respiratory specialists, and with first-move advantage, Respiri offers an over-the-counter monitoring solution that will help people manage asthma in ways that have never been available before.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
Respiri eyes maiden 2021 revenue of $6-8m
Health & Biotech
Respiri patient trial, bottom line both on track
Health & Biotech
US FDA approval is on the agenda for these 5 ASX small caps
Health & Biotech
Respiri links up with BNPL rocket Zip Co
News
Closing Bell: Today’s biggest small cap movers on the ASX
Health & Biotech
Respiri’s biggest deal yet gives it access to the world
News
10 at 10: These ASX stocks are testing their arsenal this morning
Health & Biotech
Respiri boss says preventative digital health has finally arrived
Health & Biotech
Respiri signs key deal with UK research centre as it prepares for European launch
Experts
Scopo’s health powerplays: Clinical trials are back
Health & Biotech
Respiri launches asthma education plan to support pharmacists
Health & Biotech
Shareholders back Respiri’s new story with strong support for capital raise
News
V-Con Recap: Here are the most important things we learned about the future of telehealth
Stockhead TV
Stockhead V-Con: The Future of TeleHealth
Health & Biotech
Respiri pushes ahead with regional expansion after signing key distribution deal
Health & Biotech
Genetic Signatures eyes big buyers after COVID-19 test approved in Oz
Health & Biotech